Lab21 has introduced an infectious disease screening diagnostic assay and has expanded the availability of its blood bank screening range of diagnostic assays.
Lab21 has recently secured 510(k) clearance in the US for its Syphilis Treponema Pallidum Haemagglutination (TPHA) assay, which is formatted to run on the Beckman Coulter PK7200 platform.
The company has also announced that it has launched a CE-marked cytomegalovirus Haemagglutination (CMV HA) assay, which has been formatted to run on both the Beckman Coulter PK7200 and 7300 platforms, where the liquid-stable reagents may provide an ease-of-use advantage.
Lab21 has also expanded its global sales into new territories in the Asia-Pacific region through the renewal and extension of a partnership with Alere.
